Breaking News
Get 40% Off 0
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance Find Stocks Now
Close

Deciphera Pharmaceuticals LLC (DCPH)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Deciphera Pharma's earnings

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
14.58 -0.09    -0.61%
22/04 - Closed. Currency in USD ( Disclaimer )
After Hours
14.58
0.00
0.00%
16:02:21 - Real-time Data
Type:  Equity
Market:  United States
  • Volume: 377,421
  • Bid/Ask: 5.96 / 15.40
  • Day's Range: 14.58 - 15.13
Deciphera Pharma 14.58 -0.09 -0.61%

Deciphera Pharmaceuticals LLC Company Profile

 
Get an in-depth profile of Deciphera Pharmaceuticals LLC, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

300

Equity Type

ORD

Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing vimseltinib, an orally administered, potent, and highly selective switch-control kinase inhibitor of colony stimulating factor 1 receptor (CSF1R) for the treatment of tenosynovial giant cell tumor (TGCT); and DCC-3116 to treat RAS/RAF mutant cancers that is in the preclinical-stage. Deciphera Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.

Contact Information

Address 200 Smith Street
Waltham, 02451
United States
Phone 781 209 6400
Fax 785 830 2150

Top Executives

Name Age Since Title
Steven L. Hoerter 50 2018 President, CEO & Director
James A. Bristol 76 2007 Independent Director
John S. Condeelis - - Member of Scientific Advisory Board
Dennis Leo Walsh 55 2015 Independent Director
Jean-Yves Blay 61 2015 Member of Scientific Advisory Board
Ron Squarer 56 2019 Independent Chairman
Filip Janku 48 2015 Member of Scientific Advisory Board
Michele De Palma - - Member of Scientific Advisory Board
John de Groot - - Member of Scientific Advisory Board
Patricia L. Allen 61 2016 Independent Director
Frank S. Friedman 65 2019 Independent Director
F. Stephen Hodi - 2015 Member of Scientific Advisory Board
John R. Martin 62 2015 Independent Director
Edward J. Benz 77 2016 Independent Director
Susan L. Kelley 68 2019 Independent Director
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

DCPH Comments

Write your thoughts about Deciphera Pharmaceuticals LLC
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Darkemme Anna
Darkemme Anna Nov 17, 2021 10:15AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Holy moly
Pieter Jan PEETERS
Pieter Jan PEETERS Nov 08, 2021 10:15AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
do you think the value could come back to 20$ before the end of the year ?
joninge kvamme
joninge kvamme Nov 05, 2021 5:47PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
The rebounce is imminent. Weak minds no need to buy stocks. Go back to lotto.
joninge kvamme
joninge kvamme Nov 05, 2021 1:21PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Dip bought ha ha ha
준호 조
준호 조 Nov 05, 2021 9:24AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
buy the dip~ lol~
Blackswan Trader
Blackswan Trader Aug 16, 2019 3:56PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
This stock gonna crash
Batuhan Babür
Batuhan Babür Aug 16, 2019 3:56PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
What a call
Jean Mercredi
Jean Mercredi Aug 16, 2019 3:56PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Wizard
Edwin Foo
Edwin Foo Aug 16, 2019 3:56PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
insider
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email